Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript

Kamada Ltd. reported strong Q2 2025 results, with revenues up 5% year-over-year to $44.8 million and adjusted EBITDA rising 20% to $10.9 million, driven by diversified product sales, notably GLASSIA ex-U.S. and VARIZIG U.S., alongside disciplined expense management. The company raised its full-year 2025 adjusted EBITDA guidance to $40-$44 million, while reiterating revenue guidance of $178-$182 million, projecting continued profitable growth. Strategic priorities include leveraging a $66 million cash position for M&A, expanding plasma collection operations with a newly FDA-approved Houston center, and advancing the pivotal Phase III InnovAATe trial towards an interim futility analysis by year-end.

Analysis

Kamada Ltd. (NASDAQ:KMDA) reported a strong financial performance for the first half of 2025, demonstrating accelerated profitability and disciplined operational management. Total revenues for the first six months grew 11% year-over-year to $88.8 million, while adjusted EBITDA surged 35% to $22.5 million, achieving a robust 25% margin. The growth was primarily driven by increased sales of GLASSIA in ex-U.S. markets and VARIZIG in the U.S., highlighting the benefit of a diversified product portfolio as contributions from former growth drivers KEDRAB and CYTOGAM remained stable. Management's confidence is underscored by an increase in full-year 2025 adjusted EBITDA guidance to $40-$44 million, representing a 23% year-over-year increase at the midpoint, while reiterating revenue guidance. Strategically, the company is advancing on multiple fronts: it received FDA approval for a new plasma collection center, which along with another center is expected to generate $16-$20 million in annual revenue at full capacity; it is expanding its biosimilar distribution business, projecting it to reach $15-$20 million in annual sales within five years; and it is progressing its pivotal Phase III InnovAATe trial, with an interim futility analysis expected by year-end 2025. With a cash balance of $66 million, the company is also actively pursuing M&A to acquire commercial-stage assets, signaling potential for inorganic growth.

Key Decisions for Investors

• Investors should note the company's improving profitability, evidenced by the raised full-year adjusted EBITDA guidance and a stated goal of maintaining margins above 25%, which supports a potentially higher valuation.
• Monitor key near-term catalysts, including the results of the InnovAATe Phase III interim futility analysis by year-end 2025 and the announcement of M&A deals funded by the company's $66 million cash position.
• Consider the successful diversification of revenue streams, but remain aware of execution risks associated with scaling the new plasma collection and biosimilar businesses to meet long-term revenue targets.
• Factor in the upcoming change in tax status, as the company expects to exhaust its tax loss carryforwards by the end of 2025, leading to an effective tax rate of 20-25% in subsequent years which will impact net earnings.